Sanofi (SNY)

49.68
0.23 0.46
NASDAQ : Health Technology
Prev Close 49.91
Open 49.86
Day Low/High 49.51 / 49.88
52 Wk Low/High 37.62 / 55.00
Volume 2.09M
Avg Volume 1.74M
Exchange NASDAQ
Shares Outstanding 2.51B
Market Cap 129.93B
EPS 1.30
P/E Ratio 27.16
Div & Yield 1.17 (2.28%)
2 Speculative Biotech Stocks for 2016

2 Speculative Biotech Stocks for 2016

Cempra and Relypsa are two high-risk, high-reward small-caps worth considering.

U.S. Carmakers Benefit the Most From Jump in European Car Sales

And four other things you need to know now.

Jim Cramer Sees a Deal on Priceline Stock, Likes Weyerhaeuser

Jim Cramer Sees a Deal on Priceline Stock, Likes Weyerhaeuser

TheStreet's Jim Cramer said to buy Priceline (PCLN) on the dip Monday while answering viewer questions from the floor of the New York Stock Exchange.

Closing Bell: Sanofi Falls on Weak Diabetes Sales; Crude Tops $46

Closing Bell: Sanofi Falls on Weak Diabetes Sales; Crude Tops $46

Stocks ended the day lower in a quieter session of trading compared to Wednesday's blowout rally.

Building a Sweet 16 Portfolio, Part 1

Selection of stocks is tailor made for investor, given market parameters.

Sanofi, Marks & Spencer Offer European Value Says S&P Capital IQ

Sanofi, Marks & Spencer Offer European Value Says S&P Capital IQ

The European economy is growing and the volatility from the Greek exit drama is keeping a lid on stock valuations.

Here Are 3 Charts Showing You Why Illumina Is a Marvel

Here Are 3 Charts Showing You Why Illumina Is a Marvel

It's almost impossible to get too excited about its success.

Obamacare Ruling Means the Debate Is Over

Obamacare Ruling Means the Debate Is Over

As health-care stocks rally, it's time for politicians to move on.

What's So Great About an Up Opening?

Don't rely on Europe; it's too out of sync with U.S.

Here's What's Driving Biotech

And it's not the favorable macroeconomic climate.

Gilead May Be the Cure for the Blues

Gilead May Be the Cure for the Blues

Gilead's Relative Strength Index slope is very strong.

Gilead May Be the Cure for the Blues

Gilead May Be the Cure for the Blues

Gilead's Relative Strength Index slope is very strong.

That's Just What's Supposed to Happen

Stocks that stabilized yesterday were terrific today.

Growth Seekers Return

Investors are seeing growth today in three areas.

Picking Up Where We Left Off

Picking Up Where We Left Off

Another quarter, another run to record highs.

Consider These Three French Companies

Consider These Three French Companies

These firms offer strong dividends, cash flow and trailing 12-month sales.

The Day Ahead: Just Another Muted Monday

The Day Ahead: Just Another Muted Monday

Welcome to another holiday-shortened week.

Is There Still a Play to Be Made on Regeneron?

Is There Still a Play to Be Made on Regeneron?

An inverse head and shoulders pattern could soon develop.

Unilife Strutting Over Sanofi Deal

Unilife Strutting Over Sanofi Deal

Syringe-seller Unilife is gaining momentum - and scaring the shorts - after signing a big deal with Sanofi, says Alan Shortall, CEO of Unilife.

Europe Makes a Comeback

Europe Makes a Comeback

When economic news is good, so are investment prospects

This Is Incredibly Bullish Behavior

This Is Incredibly Bullish Behavior

Most stocks seem unable to stop once propelled higher.

Small IPOs Bring Risks

Small IPOs Bring Risks

Gladstone Land, KaloBios Pharmaceuticals and Stemline Therapeutics plan to go public, IPO Desktop President Francis Gaskins isn't sure the risk is worth it.

Blown Away by Transports, Drugs

Blown Away by Transports, Drugs

Not so much by the financials.

Don't Wait to Buy Wells Fargo, Sanofi

Don't Wait to Buy Wells Fargo, Sanofi

Jeanie Wyatt, CEO of South Texas Money Management, names her favorite stocks including Wells Fargo and Sanofi.

Europe: Down but Not Out

Europe: Down but Not Out

Despite the economic travails, it has companies that are doing well.

3 Cancer-Drug Stocks Look Strong

3 Cancer-Drug Stocks Look Strong

These drug companies addressing prostate cancer get high grades from my guru strategies.

Sour on Sanofi

Sour on Sanofi

This drugmaker has fallen from a nine-month high to a key support level in just five sessions.

Two Drug Stocks Offer Trade Setups

Two Drug Stocks Offer Trade Setups

Forest Labs has potential volatility and high short interest, and Sanofi has crossed some key levels.

Buy SNY under $35

Buy SNY under $35

Stephanie Link, director of research for TheStreet, explains why Sanofi is an attractive investment under $35.

3 Stocks I Saw on TV, January 30

3 Stocks I Saw on TV, January 30

Dan Fitzpatrick examines three stocks viewed on Fast Money. Today's stocks include Sanofi-Aventis, Cypress Semiconductor and Biogen.